Diets · Metabolic & Cardiometabolic
ketogenic diet with SGLT2 inhibitor causes euglycemic ketoacidosis
In plain terms: Can keto plus a diabetes drug cause dangerous ketoacidosis?
Yes, combining a very low-carb diet with an SGLT2-inhibitor drug is a genuine, well-documented risk even when blood sugar looks normal.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Combining a ketogenic diet with an SGLT2-inhibitor drug raises the risk of euglycemic diabetic ketoacidosis - a genuine, dangerous interaction to flag for any diabetic family member.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mistry 2021 2021 · AACE Clin Case Rep | observational | supports | low | [FT-verified] Mistry 2 pts+review euDKA SGLT2i+keto; pharmacovigilance-grade |
| Koutentakis M et al 2023 · study_type: mechanism | observational | supports | moderate | Narrative review of SGLT2i ketogenic mechanism explicitly addressing 'benefits and risks of combining SGLT-2 inhibitors with the ketogenic diet,' incl. ketoacidosis risk |
| Guirguis 2022 · Clin Med Insights Case Rep | observational | supports | low | severe DKA after keto started 1mo into empagliflozin; low-carb+SGLT2 a set-up |
| Needham N et al 2023 · medRxiv | observational | supports | moderate | Pilot ketogenic-diet trial in bipolar disorder (n=27); 1 serious adverse event = euglycemic ketoacidosis in a participant concurrently taking an SGLT2 inhibitor |
| Peters 2020 · Diabetes Care | RCT | supports | high | pooled inTandem: sotagliflozin+insulin raised DKA in T1D but dose-dependent/mitigable |
| Juneja D et al 2023 · study_type: observational | observational | supports | low | Systematic meta-summary of 108 case reports/17 series, n=169 SGLT2i-EDKA patients; trigger identified in 78.7%, commonest = acute severe infection (37.9%); diet not reported as a top trigger category |
| Kamath SD et al 2024 · study_type: observational | observational | supports | low | 58F T2DM on dapagliflozin 1yr; EDKA during illness w/ low carbohydrate intake + dehydration + 2 missed insulin doses cited as co-precipitants; BOHB 5.4 mmol/L |
| Garg R et al 2025 · study_type: mechanism | mechanism | mixed | moderate | Narrative review of 6 non-diabetic SGLT2i euDKA cases; mechanism = 'general state of starvation or relative insulin deficiency' exacerbating baseline SGLT2i ketonemia; common risk factor was decreased oral intake, not diet type |
| Somagutta 2022 2022 · Korean J Fam Med | observational | supports | low | [FT-verified] Somagutta SR 13 reports/14 pts keto+SGLT2i euDKA; consistent case signal |
| Roberts 2025 · Diabetes Obes Metab | observational | supports | moderate | review: VLCKD/keto raise ketones and DKA risk with/without diabetes; risk poorly documented |
| Earle 2020 · Clin Pract Cases Emerg Med | observational | supports | low | euDKA with very-low-carb diet + canagliflozin; diet compounds SGLT2 risk |
| Latif 2020 · BMJ Case Rep | observational | supports | low | euDKA in T2DM after 2wk keto on empagliflozin; glucose only 169 mg/dL |
| Woronow 2024 · Endocr Pract | observational | supports | moderate | FDA pharmacovigilance: prolonged/relapsed ketoacidosis with SGLT2i in T2DM |
| Dynka D, et al. 2026 · Ann Med | observational | supports | moderate | [FT-verified] 2025 KD-safety review flags SGLT2i interaction caution |
| Steinmetz-Wood 2020 · Case Rep Endocrinol | observational | supports | low | DKA in T2DM on empagliflozin + keto; SGLT2+keto critical trio missed initially |
| Patel K et al 2022 · study_type: mechanism | observational | supports | moderate | Review of SGLT2i-induced euDKA mechanism (glucagon/insulin ratio rise from glucosuria); explicitly lists 'ketogenic diet' alongside illness/surgery/pregnancy as a precipitating factor |
| Colacci 2022 · Can J Diabetes | meta-analysis | supports | high | meta-analysis: SGLT2 inhibitors increase DKA risk vs comparators in T2DM |
| Kapila 2021 · Cureus | observational | supports | low | euDKA 1 day post-bariatric in T2DM on canagliflozin + 3-wk keto; low-carb/postop triggers |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.